LadRx Announces Reverse Stock Split - Seite 3

About LadRx
LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, LadRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S (now Zevra Therapeutics) in exchange for milestone payments and royalties. Zevra is developing arimoclomol and is currently focused on Niemann-Pick disease Type C (NPC). LadRx Corporation’s website is www.ladrxcorp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005366/en/

The LadRx Corporation Stock at the time of publication of the news with a fall of -20,87 % to 0,091USD on Stuttgart stock exchange (10. Mai 2023, 08:01 Uhr).